GenMark Diagnostics (GNMK) Reports In-Line Q4 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Needham & Company Reiterates Buy on GenMark Diagnostics (GNMK) Following 4Q
March 1, 2017 7:34 AM ESTNeedham & Company reiterated a Buy rating and $15.00 price target on GenMark Diagnostics (NASDAQ: GNMK) following the company's 4Q earnings report. GNMK's 4Q16 revenue was $14.9M. And its GAAP EPS was ($0.27) vs. consensus of ($0.27).
Analyst Mike Matson commented, "GNMK's 4Q16 revenue was consistent with... More
